tretinoin and Parkinsonian-Disorders

tretinoin has been researched along with Parkinsonian-Disorders* in 3 studies

Reviews

1 review(s) available for tretinoin and Parkinsonian-Disorders

ArticleYear
Generation of dopaminergic neurons from embryonic stem cells.
    Journal of neurology, 2002, Volume: 249 Suppl 2

    Neuronal transplantation is considered to be a promising therapeutic approach to neurodegenerative diseases. In addition to fetal tissues and neural stem cells, embryonic stem cells are good candidates for the creation of neurons. We have recently identified a stromal cell-derived inducing activity that promotes neural differentiation of mouse embryoric stem cells. This activity accumulated on the surface of PA6 stromal cells and induced efficient neuronal differentiation of co-cultured embryonic stem cells under serum-free conditions without the use of either retinoic acid or embryoid bodies. A high proportion of tyrosine hydroxylase-positive neurons producing dopamine are obtained. Induction of neurons with stromal cell-derived inducing activity may be a useful new method for basic neuroscience research and therapeutic applications, including cell transplantation therapy for Parkinson's disease.

    Topics: Animals; Cell Differentiation; Coculture Techniques; Dopamine; Mice; Nerve Growth Factors; Neurons; Oxidopamine; Parkinsonian Disorders; Stem Cell Transplantation; Stem Cells; Stromal Cells; Tretinoin

2002

Other Studies

2 other study(ies) available for tretinoin and Parkinsonian-Disorders

ArticleYear
Cytosolic catechols inhibit alpha-synuclein aggregation and facilitate the formation of intracellular soluble oligomeric intermediates.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2006, Sep-27, Volume: 26, Issue:39

    Aberrant aggregation of alpha-synuclein (alpha-syn) to form fibrils and insoluble aggregates has been implicated in the pathogenic processes of many neurodegenerative diseases. Despite the dramatic effects of dopamine in inhibiting the formation of alpha-syn fibrils by stabilization of oligomeric intermediates in cell-free systems, no studies have examined the effects of intracellular dopamine on alpha-syn aggregation. To study this process and its association with neurodegeneration, intracellular catechol levels were increased to various levels by expressing different forms of tyrosine hydroxylase, in cells induced to form alpha-syn aggregates. The increase in the steady-state dopamine levels inhibited the formation of alpha-syn aggregates and induced the formation of innocuous oligomeric intermediates. Analysis of transgenic mice expressing the disease-associated A53T mutant alpha-syn revealed the presence of oligomeric alpha-syn in nondegenerating dopaminergic neurons that do contain insoluble alpha-syn. These data indicate that intraneuronal dopamine levels can be a major modulator of alpha-syn aggregation and inclusion formation, with important implications on the selective degeneration of these neurons in Parkinson's disease.

    Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Amino Acid Substitution; Animals; Catechols; Cell Differentiation; Cell Line, Tumor; Cerebral Cortex; Corpus Striatum; Cytosol; Dopamine; Humans; Levodopa; Mice; Mice, Transgenic; Mutation, Missense; Nerve Degeneration; Neuroblastoma; Oxidation-Reduction; Parkinson Disease; Parkinsonian Disorders; Protein Conformation; Recombinant Fusion Proteins; Solubility; Transfection; Tretinoin; Tyrosine 3-Monooxygenase

2006
Identification of the protein disulfide isomerase family member PDIp in experimental Parkinson's disease and Lewy body pathology.
    Brain research, 2004, Oct-01, Volume: 1022, Issue:1-2

    Parkinson's disease (PD) is a slowly progressing neurodegenerative disorder with no clear etiology. Pathological hallmarks of the disease include the loss of dopaminergic neurons from the substantia nigra (SN) and the presence of Lewy bodies (LBs) (alpha-synuclein and ubiquitin-positive, eosinophilic, cytoplasmic inclusions) in many of the surviving neurons. Experimental modeling of PD neurodegeneration using the neurotoxins 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 1-methyl-4-phenyl-pyridinium (MPP(+)) has identified changes in gene expression of different endoplasmic reticulum (ER) stress proteins associated with MPTP- and PD-related neurodegeneration. We show that the protein disulfide isomerase (PDI) family member pancreatic protein disulfide isomerase (PDIp), previously considered exclusively expressed in pancreatic tissue, is uniquely upregulated among PDI family members within 24 h following exposure of retinoic acid (RA)-differentiated SH-SY5Y human neuroblastoma cells to either 1 mM MPP(+) or 10 microM of the highly specific proteasome inhibitor lactacystin. RT-PCR confirms PDIp expression in brain of post-mortem human PD subjects and immunohistochemical studies demonstrate PDIp immunoreactivity in LBs. Collectively, these findings suggest that increased PDIp expression in dopaminergic (DA) neurons might contribute to LB formation and neurodegeneration, and that this increased PDIp expression may be the result of proteasome impairment.

    Topics: 1-Methyl-4-phenylpyridinium; Acetylcysteine; Aged; Aged, 80 and over; Analysis of Variance; Animals; Blotting, Northern; Blotting, Western; Cell Differentiation; Cell Line, Tumor; Dopamine; Female; Gene Expression Regulation; Humans; Immunohistochemistry; Lewy Bodies; Male; Middle Aged; Neuroblastoma; Nuclear Proteins; Parkinsonian Disorders; Postmortem Changes; Rats; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Time Factors; Tretinoin

2004